K.M. has no conflict of interest to disclose. Y.N. has received research grant from Takeda Pharmaceutical Co.. N.S. teaches a course endowed by CSL Behring. S.F. taught a course endowed by CSL Behring, and has received personal fees from Chugai Pharmaceutical Co., Ltd., CSL Behring, and Takeda Pharmaceutical Co.. K.O. taught a course endowed by CSL Behring and has received personal fees from Chugai Pharmaceutical Co., Ltd. and CSL Behring. M.T. has received personal fees from Chugai Pharmaceutical Co., Ltd. KM Biologics Co., Bayer AG, and CSL Behring. K.N. has received grants, personal fees, and non-financial support from Chugai Pharmaceutical Co., Ltd., personal fees from F. Hofmann-La Roche Ltd., grants, personal fees, and non-financial support from Sysmex Co. and Sekisui Medical, grants and personal fees from Takeda Pharmaceutical Co., grants and personal fees from Sanofi S.A, personal fees from CSL Behring Co., grants and personal fees from KM Biologics Co., grants and personal fees from Novo Nordisk A/S, grants and personal fees from Bayer AG, grants and personal fees from Bioverativ Inc., and grants and personal fees from Shire Plc, personal fees from Fujimoto Seiyaku and is an inventor of the patents relating to emicizumab.